Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 24Leukemia, Myeloid, Chronic-Phase 4Leukemia 3Bronchiolitis Obliterans Syndrome 3Philadelphia Chromosome 2Myeloproliferative Disorders 2Leukemia, Myeloid 2Recurrence 1Hematologic Diseases 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Imatinib Mesylate 12nilotinib 3bosutinib 3peginterferon alfa-2a 2asciminib 2Dasatinib 2Azacitidine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2venetoclax 1thymoglobulin 1flumatinib 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Vincristine 1Tyrosine Kinase Inhibitors 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Melphalan 1Interferons 1Dexamethasone 1Clofarabine 1Busulfan 1Bone Marrow Transplantation 1Blood Specimen Collection 1Antilymphocyte Serum 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Philadelphia Chromosome × asciminib × Myeloid × Clear all
NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡